One of the most powerful ways to reduce the risk of complications is to keep blood sugar levels in a healthy range, which is why early, effective treatment is so important
Semaglutide, marketed as Ozempic for diabetes and Wegovy for obesity, has emerged as the commercial powerhouse, with the oral version launching in January 2026 following December 2025 FDA approval [3]
Dose is gradually adjusted by your provider based on your individual progress
Tesamorelin Dosage: What Clinics Are Actually Prescribing Standard Clinical Protocol The FDA-approved dose for Egrifta is 2 mg administered subcutaneously once daily
For example, the SELECT trial reported that semaglutide reduced the risk of MACE by 20% (Hazard Ratio (HR) 0.80, 95% confidence interval (CI) 0.720.90) in people with obesity but without diabetes, although several secondary outcomes did not reach statistical significance under hierarchical testing procedures
Selenoprotein K (selenok) also plays a vital role in calcium influx in immune cells [13,22]
